Comparison · NCT04335123-sae
Open Label Losartan vs External Controls: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Open Label Losartan vs External Controls: serious adverse events. Trial comparisons, record NCT04335123-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04335123-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.114 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0771 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.0771 | 0.114 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Open Label Losartan | 34 patients with COVID-19 and respiratory failure participated in the study and were placed on losartan 25 mg once daily on study day 0. Losartan dose was increased to 50 mg once daily on study day 3. Participants continued losartan until they experienced resolution of respiratory failure (normal oxygen levels on room air), were discharged from the hospital, met stoppage criteria or completed 14 days of therapy.~Losartan: 25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion | 0 | 30 | EG000 |
| Group 2 | External Controls | 46 external controls matched to losartan participants upon baseline characteristics. | 0 | 46 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From enrollment to hospital discharge, up to day 14.
Source ClinicalTrials.gov
Trial
- Title
- Study of Open Label Losartan in COVID-19
- NCT number
- NCT04335123
- Phases
- PHASE1
- Conditions
- COVID-19
- Interventions
- Losartan
- Lead sponsor
- University of Kansas Medical Center
- Results first posted
- 2024-08-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04335123?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04335123-sae